

meet in italy
FOR LIFE SCIENCES
STARTUP BREEDING 2023

MEET IN ITALY FOR LIFE SCIENCES 2023
Startup Breeding 2023 - Final Pitching Event

31st October 2023
Palazzo Mezzanotte - Milan

Discover the selected startups for Startup Breeding 2023
and their innovative proposals



Meet in Italy for Life Sciences - MIT4LS - the leading international partnering event in the Life Sciences sector in Italy – shows a special attention for startups, with over 660 startups participating in the networking sessions along seven editions.


MIT4LS is powered by the **National Technological Cluster for Life Sciences - ALISEI**, which associates all the main organizations working for the promotion and growth of the Life Sciences sector in Italy, from research to industry. At international level, it is supported by **Enterprise Europe Network - EEN**, that promotes the internationalization of European SMEs and supports the event since its first edition, with several of its 600 members.

MIT4LS Startup Breeding is the initiative dedicated to startups and business proposals. The goal is to provide them with the expertise, tools and connections to boost and fully exploit their business potential, thanks to the support of a wide network of startup mentors, coaches, experts and several investors.

At the end of the training, the selected finalists will pitch their proposals in occasion of **Meet in Italy for Life Sciences 2023 - Final Event, in Milan, on the 31st October 2023**.

Startup Breeding 2023

PARTNERS



Startup Breeding 2023

FINALIST STARTUPS

OVERVIEW



CHRONOLIFE
Real Time Intelligence
for Healthcare

Chronolife is developing a remote patient monitoring service, Keesense, based on a connected medical T-shirt and its smartphone application. Keesense has been designed to be as comfortable and easy to use as possible. The solution interfaces with several remote monitoring platforms, enabling our customers (hospitals, healthcare professionals) to choose the most suitable



CLEPIO Biotech
3D histology, made
easy

The company offers an innovative technology for 3D quantification of histological biomarkers. Their goal is to create a new standard for the analysis of cancer tissue biopsies, where the full 3D volume of the sample is considered instead of the current standard where one or few 2D slices are used, losing more than 99% of the available information.



GENESYS
Medical Devices,
pathogens' genetic
signature detection
system

GeneSys emerged from the urgent need for a groundbreaking PCR-based solution, enabling rapid pathogen monitoring in under 1 hour, anytime, anywhere. Its initial focus is on swiftly detecting urinary tract infections, prevalent among elderly and hospitalized individuals.



MEEVA
Innovating therapies
for autistic youth

Nowadays, MEEVA is on a mission to provide universal access to therapies for all autistic teens. We have developed a digital solution leveraging Virtual Reality and ML-based data analytics fostering social skills through a multi-player serious game.



NANORADOX
Medical Device for
oncological disease

Vision S.p.a. ("Vision") develops a medical device for the treatment of Head and Neck Cancers (HNC) through localized hyperthermia. They have identified an unmet medical need in the treatment of HNC and worked on a non-invasive solution that would allow patients a longer and good quality life, "Nanoradox®".



PAPERBOX HEALTH
Intervention in
neurodevelopmental
disorders

Paperbox Health aims to empower every child, ensuring their potential isn't limited by learning challenges. Through their solution, DINO, a game-based approach, they're breaking down accessibility barriers, enabling early identification and effective intervention on neurodevelopmental disorders.



PREVIENI
Medical Imaging of
soft and hard tissues

Previeni aims at bridging the diagnostic gap left unserved by the current state of the art in medical imaging by offering doctors the possibility to see inside their patients right on the field, at their home, or their room bed, without requiring a critical patient to move, and without harming the patient with the usage of harmful ionizing radiation as found in portable x-ray machines.



RESALIS
Tackling metabolic
disorders with non-
coding RNAs

Resalis is developing a first-in-class antimiR-22 therapeutic (RES-010) to address highly unmet medical needs in metabolic liver diseases. RES-010 is an antisense oligonucleotide that targets miR-22 and is designed to become a safe and convenient treatment option with durable disease-modifying therapeutic impact.



SOUNDSAFE Care
For a safe and sound
surgical care

Nowadays, chemotherapy and radiotherapy are well-established approaches to treat cancer but they are not free from invasiveness. Soundsafe Care can improve the lives of millions of patients by introducing a novel integrated robotic device for performing focused ultrasound surgery on oncological organs in a totally non-invasive manner using focused ultrasound (FUS).



TTOP
True Tissue On
Platform

TTOP is a modular, versatile MicroPhysiological platform that aims at improving the effectiveness of preclinical prediction guaranteeing more predictive results than conventional technologies, replicating complex human pathophysiological conditions and minimizing the controversial animal use in research.



VRG Therapeutics
Generation of
miniproteins for
therapeutic use

VRG Therapeutics (VRG Tx) is an innovative biopharmaceutical R&D company head quartered in Budapest, Hungary. VRG Tx is committed to leveraging its proprietary miniprotein ISEP technology to tackle diseases through mechanisms that conventional biopharmaceutical approaches cannot achieve.